Eli Lilly announced the acquisition of gene-editing biotech Verve Therapeutics for up to $1.3 billion, acquiring full rights to Verve's PCSK9-targeting program aimed at one-time cardiovascular disease treatments. The deal follows early clinical data showing LDL cholesterol reductions without liver enzyme elevations. Lilly’s move aligns with its strategic expansion in genetic medicines, complementing its existing cardiometabolic portfolio and ongoing gene therapy collaborations. Verve’s lead candidate, VERVE-102, holds Fast Track designation and is in Phase 1b trials.